Wall Street Zen upgraded shares of HUTCHMED (NASDAQ:HCM - Free Report) from a buy rating to a strong-buy rating in a research report report published on Friday.
Separately, HSBC downgraded HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
View Our Latest Research Report on HUTCHMED
HUTCHMED Price Performance
HUTCHMED stock traded down $0.24 during midday trading on Friday, reaching $15.10. The company's stock had a trading volume of 37,205 shares, compared to its average volume of 100,388. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $21.50. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.83 and a quick ratio of 2.70. The stock's 50 day simple moving average is $14.77 and its 200 day simple moving average is $14.65.
Institutional Investors Weigh In On HUTCHMED
A number of hedge funds and other institutional investors have recently bought and sold shares of HCM. Barclays PLC increased its position in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after buying an additional 2,255 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in shares of HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after buying an additional 899 shares in the last quarter. Summit Trail Advisors LLC increased its position in shares of HUTCHMED by 7.7% in the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after buying an additional 1,004 shares in the last quarter. OLD Mission Capital LLC purchased a new position in shares of HUTCHMED in the fourth quarter valued at $230,000. Finally, Marshall Wace LLP purchased a new position in shares of HUTCHMED in the fourth quarter valued at $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
